)
Phathom Pharmaceuticals (PHAT) investor relations material
Phathom Pharmaceuticals Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial progress
VOQUEZNA launched at the end of 2023; sales were $55 million in its first full commercialization year and $175 million last year, with FY2026 guidance of $310 million-$325 million.
Indicated for erosive esophagitis and non-erosive reflux, VOQUEZNA provides elevated stomach pH over 24 hours and targets patients who remain symptomatic on PPIs.
In market research, 97% of surveyed gastroenterologists viewed VOQUEZNA as a better treatment for heartburn patients.
Prescribing access and GI growth
Commercial coverage exceeds 80% of lives and has been generally stable; the key prescribing friction is prior authorization workflow and physician confidence in fulfillment, rather than a change in coverage.
BlinkRx supports PA submission, resubmissions and appeals, and offers cash pay when insurance does not cover the drug; commercial patients using BlinkRx can access a $0 copay versus $25 through retail.
The GI path to $1 billion in sales targets 20%-30% of 20 million annual acid-suppression prescriptions; VOQUEZNA currently represents 5%-6% of those scripts.
Broader use depends on moving from the most severe patients to moderately severe patients as physicians gain confidence in treatment and fulfillment.
Primary care and promotion
A further $1 billion sales opportunity is envisioned in primary care; current sales calls are 70% GI and 30% primary care, with plans to broaden primary-care capabilities over time.
Digital DTC outreach restarted in 2026 after much promotion was paused in H2 2025; channel pilots are starting modestly, with investment to grow where ROI is positive.
A newly started as-needed dosing study is part of the primary-care expansion strategy, addressing patients seeking an alternative to daily PPI therapy.
- GI-led growth, upcoming label expansions, and a potential >$1B OTC market shape the outlook.PHAT
Stifel 2026 Healthcare Conference 2026 - GI-led growth and improving access support a path to broader primary-care and OTC opportunities.PHAT
3rd Annual Guggenheim Healthcare Innovation Conference - VOQUEZNA growth and profitability advance alongside expansion into new GI indications.PHAT
Corporate presentation - Revenue rose 71%, cash flow stayed positive, and VOQUEZNA exclusivity faces litigation.PHAT
Q3 2026 - Voquezna’s growth accelerates with robust revenue, expanding indications, and strong prescriber confidence.PHAT
H.C. Wainwright 28th Annual Global Investment Conference - Rapidly growing reflux therapy targets $2B+ peak sales, with strong adoption and pipeline expansion.PHAT
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 revenue up 88% to $74.3M, prescriptions surged, and operating profit achieved.PHAT
Q2 2026 - VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity.PHAT
Corporate presentation - VOQUEZNA's launch fueled $55.3M revenue, 300K+ scripts, and strong cash for 2025 growth.PHAT
Q4 2024
)
)
)
)
)
)
)
)